Aspira Women's Health raises ~$5.5M in offering; preliminary cash $2.6M as of Dec 31, 2023

Aspira Women's Health Inc.

Gross proceeds of ~$5.5M from sale of 1,371,000 shares at $3.50/share plus warrants.
CEO Nicole Sandford participated in offering; also sold 2,400 shares at $4.255/share.
Preliminary cash and equivalents of $2.6M as of Dec 31, 2023, excluding $0.3M restricted cash.
Existing warrants with exercise price of $13.20 amended to $4.00, expiration extended to Jan 2029.
Offering is expected to close Jan 26, 2024.

item 1.01 item 2.02 item 3.02 item 3.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aspira Women's Health Inc. entered into Securities Purchase Agreement with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company valued at gross proceeds to the Company from the Offering are expected to be approximately $5.5 million (effective 2024-01-24).

Action: entry
Agreement: equity purchase
Counterparty: a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company
Value: gross proceeds to the Company from the Offering are expected to be approximately $5.5 million
Effective: 2024-01-24

Exact text from the filing

) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Aspira Women's Health Inc. amended certain existing warrants (effective 2024-01-26).

Action: amendment
Effective: 2024-01-26

Exact text from the filing

The Company has also agreed that certain existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $13.20 per share and a termination date of August 25, 2027, will be amended, effective upon the closing of the Offering, so that the amended warrants will have a reduced exercise price of $4.00 per share and a new termination date of January 26, 2029.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aspira Women's Health Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds generated from the Offering (effective 2024-01-24).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners
Value: 7.0% of the aggregate gross proceeds generated from the Offering
Effective: 2024-01-24

Exact text from the filing

On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-015576

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.